GlassScriptPhysician profile
Bhavisha Patel
NPI 1407134505
$3,941.24
in general payments reported to CMS, 2019-2025
19 companies · $1,140 in 2025
The $1,140 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $174 · 2021: $248 · 2022: $635 · 2023: $631 · 2024: $868 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.49 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,186.07 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,132.62 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $261.47 | 2021-2025 | |
| Amgen INC. | $246.37 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $213.22 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $170.15 | 2019-2025 | Hizentra, Andembry |
| Genentech USA, INC. | $143.67 | 2021-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $141.34 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $90.59 | 2022-2024 | Cuvitru |
| Ionis Pharmaceuticals, INC. | $62.35 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $57.87 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.61 | 2019-2023 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $39.13 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $32.06 | 2025 | |
| Aimmune Therapeutics, INC. | $27.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.03 | 2021 | |
| Covis Pharma Gmbh | $23.80 | 2021 | |
| Kaleo, INC. | $14.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.